Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2023 | Updates in the treatment of R/R LBCL: promising novel agents in the pipeline

Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses exciting updates in the treatment and management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Osborne highlights promising agents in the pipeline, including tafasitamab-lenalidomide and loncastuximab tesirine (lonca-T), and emphasizes the importance of determining the optimal sequencing of these agents. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Roche, Takeda, Pfizer, Servier, Kite Gilead, MSD, Novartis, Beigene, Astra Zeneca, Syneos, Autolus, Kyowa Kirin, Abbvie, Incyte, BMS/Celgene, Janssen